First Implant Completed in Pivotal Study of GORE® TAG® Thoracic Branch Endoprosthesis
Enrollment begins on new clinical study for the first device designed specifically for the endovascular treatment of aortic arch lesions
First Successful Implant of GORE® SYNECOR Biomaterial in a Ventral Hernia Patient
Unique biomaterial for hernia repair implanted for the first time in Gore’s Clinical Quality Improvement project
Global Vascular Thought Leaders Document Shift toward Individualizing Patient Care in Surgical Bypass
Presentations and Discussions from the Surgical Bypass Summit Available at www.surgicalbypass.com
Gore Announces Positive Results from REDUCE Clinical Study for PFO Closure
Study met its primary endpoint with PFO closure in conjunction with antiplatelet therapy, reducing recurrent stroke by > 75% over antiplatelet therapy alone
Gore Joins Vascular and Endovascular Leaders in Recognizing the 2016 Pioneers in Performance for North America
Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy
FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access
Flexibility and Durability to Aid Hemodialysis Patients
Gore REDUCE Clinical Study Completes Enrollment
Study of Closure of Patent Foramen Ovale (PFO) in Stroke Patients Reaches Major Milestone
Gore Marks Two-Year Primary Endpoint Follow-up Milestone in Study of GORE® CARDIOFORM Septal Occluder for Patent Foramen Ovale (PFO) Closure
Completion of follow -up paves way for REDUCE Clinical Study data submission to FDA for PFO indication
Gore Presents Astronaut and Scientist Mae C. Jemison, MD, as Keynote Speaker at Women in Vascular Leadership Luncheon
The pioneering Dr. Jemison, who flew aboard the Space Shuttle Endeavour, will address vascular surgeons at the 2014 SCVS symposium in Carlsbad, Calif.
Market-leading TEVAR Device is First to Surpass 100,000 Devices Distributed Worldwide
Proven, durable device leads the market, continues to impact lives